ALEXION PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT00844428
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00844545
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00838513
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
- Conditions
- Hypophosphatasia (HPP)
- Interventions
- Biological: asfotase alfa
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT00744042
- Locations
- 🇺🇸
Vanderbilt Children's Hospital, Nashville, Tennessee, United States
🇺🇸Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸St. John's Hospital, Springfield, Missouri, United States
Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
- Conditions
- Hypophosphatasia (HPP)
- Interventions
- Biological: Asfotase Alfa
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00739505
- Locations
- 🇺🇸
Barnes Jewish Hospital- Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇨🇦Department of Pediatrics & Child Health, Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, Manitoba, Canada
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00727194
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00675844
- Locations
- 🇺🇸
Clinical Trial Site, Dallas, Texas, United States
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
- Conditions
- B-cell Chronic Lymphocytic LeukemiaMultiple Myeloma
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00648739
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
- Conditions
- Allergic Asthma
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2009-01-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00485576
- Locations
- 🇨🇦
Hospital Laval, Ste-Foy, Quebec, Canada
🇨🇦McMaster University, Hamilton, Ontario, Canada
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
- Conditions
- Hemoglobinuria, Paroxysmal
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT00438789
- Locations
- 🇺🇸
Anthony Botti, Livingston, New Jersey, United States